AirFluSal MDI: a new LABA/corticosteroid inhaler

AirFluSal MDI (salmeterol/fluticasone) is indicated for the regular treatment of asthma where use of a combination product containing a long-acting ß2-agonist and an inhaled corticosteroid is appropriate.

by Sandhiya Sodha
AirFluSal MDI (salmeterol/fluticasone) is available in two strengths: 25/125 microgram and 25/250 microgram.
AirFluSal MDI (salmeterol/fluticasone) is available in two strengths: 25/125 microgram and 25/250 microgram.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package